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Simultaneous measurement of excitation-
contraction coupling parameters identiﬁes
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of hiPSC-derived cardiomyocytes
Berend J. van Meer 1, Ana Krotenberg1, Luca Sala1,6, Richard P. Davis 1, Thomas Eschenhagen 2,3,
Chris Denning4, Leon G.J. Tertoolen1 & Christine L. Mummery1,5*
Cardiomyocytes from human induced pluripotent stem cells (hiPSC-CMs) are increasingly
recognized as valuable for determining the effects of drugs on ion channels but they do not
always accurately predict contractile responses of the human heart. This is in part attribu-
table to their immaturity but the sensitivity of measurement tools may also be limiting.
Measuring action potential, calcium ﬂux or contraction individually misses critical information
that is captured when interrogating the complete excitation-contraction coupling cascade
simultaneously. Here, we develop an hypothesis-based statistical algorithm that identiﬁes
mechanisms of action. We design and build a high-speed optical system to measure action
potential, cytosolic calcium and contraction simultaneously using ﬂuorescent sensors. These
measurements are automatically processed, quantiﬁed and then assessed by the algorithm.
Multiplexing these three critical physical features of hiPSC-CMs allows identiﬁcation of all
major drug classes affecting contractility with detection sensitivities higher than individual
measurement of action potential, cytosolic calcium or contraction.
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Human induced pluripotent stem cell derived cardiomyo-cytes (hiPSC-CM) are increasingly used to studymechanisms underlying drug responses and disease
in vitro, with action- or ﬁeld potential measurements by micro-
electrode arrays translating well to clinically relevant arrhythmia
or cardiotoxicity classiﬁcation1–4. Pharma and regulatory autho-
rities are thus already implementing such approaches in early
drug discovery and cardiotoxicology assessment. However, ana-
lytical methods that relate these electrophysiological parameters
to contraction and cytosolic calcium transients, also salient fea-
tures of cardiomyocyte physiology, are still limited. This makes
clinically relevant interpretation of drug responses affecting car-
diomyocyte contractility challenging5.
Under normal conditions, contraction is the result of excitation-
contraction coupling (EC coupling). This is a complex cascade of
ion channel activities, internal calcium storage and contractile ﬁla-
ment availability with the action potential (AP), cytosolic calcium
ﬂux (Ca) and the actual contraction (Co) being the most important
physical transients6. The mechanisms of action (MOAs) through
which cardioactive drugs affect contraction typically target ion
channels or -pumps, adenosine-, muscarinic- and adrenergic
receptors, phosphodiesterases (PDE), myosin or elements of thin
ﬁlaments such as troponin C. The effect of some of these cardi-
oactive drugs would not be expected in hiPSC-CM cultures (for
example, antagonists of adrenergic and adenosine receptors require
the presence of respective agonists in the culture medium) while
often the effect of other drugs would be expected but is undetectable
because of hiPSC-CM immaturity7. Improving hiPSC-CM maturity,
either by altering cellular conﬁguration (e.g. 2D or 3D and cell
alignment, which is highly correlated with maturity)8–10 or reﬁned
measurement methods11 are factors reported to overcome the lack
of response in such cases, but are still limited in providing
mechanistic insight into hiPSC-CM pharmacological responses.
Measurement methods that give insight into AP, Ca and Co
simultaneously are needed and they would allow assessment of the
complete EC coupling of a single cardiomyocyte beat cycle and
thereby reducing data variability and experimental bias compared to
asynchronous measurements. We therefore hypothesize that
simultaneous quantiﬁcation of the changes of AP, Ca and Co in
response to drugs will provide insight into the contractile MOA
affected, higher detection sensitivity of those mechanisms and allow
proper contractile risk classiﬁcation of drugs.
We thus report the development of tools to gain the neces-
sary mechanistic insight into hiPSC-CM physiology. First,
building on literature, we develop a hypothesis-based statistical
analysis algorithm to test the likelihood of occurrence for each
of the most important mechanisms via which drugs affect
cardiomyocyte contractility. Next, we engineer a high-speed
system capable of measuring and quantifying AP, Ca and Co
simultaneously by means of ﬂuorescent sensors ANNINE-
6plus, Rhod-3 and CellMask Deep Red in combination with our
recently developed optical contraction software tool
MUSCLEMOTION12. Using this Triple Transient Measure-
ment (TTM) system we measure and quantify the response of
commercial hiPSC-CMs to a set of drugs that covers the
complete range of potentially affected contractile mechanisms.
We ﬁnd that simultaneous TTM in combination with our
algorithm allows automatic and unbiased identiﬁcation of the
MOAs affected by the test set of compounds and increased the
sensitivity of detecting contractile MOAs compared to separate
assessment of AP, Ca and Co.
Results
Hypothesis table. To develop an algorithm capable of identifying
contractile MOAs affected in response to drugs, we ﬁrst
inventoried potential effects on the kinetics of cardiomyocyte AP,
Ca and Co. A schematic is shown in Fig. 1. Three general possi-
bilities deﬁned the ﬁrst set of categories: enhanced contraction
(Co+), reduced contraction (Co−) and no effect on contraction
(Co=). The most important contractile MOAs underlying Co+
in cardiomyocytes are (i) CoþCa: increased free cytosolic calcium
concentration ([Ca2+]i) via for example calcium- and sodium
channel agonists13,14, cardiac glycosides15 and human ether-a-go-
go related gene (hERG) channel blockers16; (ii) CoþMyosin: direct
thick- or thin myosin ﬁlament activation17 or (iii) CoþcAMP:
enhancement of the complete contractile cascade via higher levels
of the second messenger 3′,5′-cyclic adenosine monophosphate
(cAMP) by beta-adrenergic stimulation18 or PDE3 inhibition19.
Main mechanisms resulting in Co− are (i) CoCa: reduction in
[Ca2+]i either via changes in the activity of the L-type calcium
channel, sarcoplasmic reticulum calcium ATPase (SERCA) or
ryanodine receptors type 220, or (ii) Cotox : via general
cardiotoxicity, often associated with mitochondrial dysfunction
or more generally with increased mitochondrial Ca2+ buffering
capacity, apoptosis and necrosis21. These Co− mechanisms do
not include contractile quiescence that occurs as a consequence of
excessive AP duration (APD) prolongation, since these com-
pounds are often Co+ before failing to repolarize in time to meet
the imposed stimulation frequency.
Two general class of drugs have been excluded in the
algorithm: beta blockers and myosin inhibitors. Since no beta-
adrenergic agonists are present in in vitro cultures with deﬁned
medium, beta blockers are not relevant in this study. Regarding
the myosin inhibitors, this group is small and the mechanisms are
not speciﬁc. For example, while blebbistatin reduces contractility,
it also affects cardiomyocyte electrophysiology22.
The expected effects on AP, Ca and Co kinetics per MOA are
listed in the hypotheses table (Table 1). Due to the heterogeneity
of the drugs within each class, it is often possible for some
compounds to have mixed or even diverse effects on the kinetic
parameters although being grouped by their main effect on Co.
For this reason, we indicated in these cases what the effects are
that, from a theoretical point of view, we do not expect for each
speciﬁc class of compound (i.e. NOT ↓; NOT ↑; NOT=). For
example, digoxin and E-4031 are both part of CoþCa, while they
shorten23 and prolong24 the action potential, respectively. While
most kinetic parameters in Table 1 are simple measurements of
parts of the waveform, action potential triangulation is calculated
as the difference between APD at 30% of repolarization and APD
at 90% of repolarization25. Triangulation is instrumental in
detecting proarrhythmic effects.
Experimental design and statistical analysis algorithm. Next,
we developed an algorithm based on standard statistics to test
whether a certain drug response is described by the effects
summarized in the Hypotheses Table. The experimental design to
test the concentration-dependent drug response in hiPSC-CMs is
shown in Fig. 2a. To eliminate variation and time-dependent
response effects, all concentrations are compared to the vehicle
(0.01% DMSO) measurements in the resulting concentration-
response plots (Fig. 2b). These vehicle measurements are also the
basis of our analysis algorithm since the probability of a kinetic
parameter not changing (‘=’ in Table 1) is equal to the probability
of it being part of the vehicle population, described by its prob-
ability density function (PDF). To determine the likelihood of a
parameter to be increased, decreased or unchanged, the PDF was
normalized to the mean and multiplied by 10 to have a range of
0–10. The resulting function was divided in three corresponding
spaces (Fig. 2c), which determine the Probability Scores (PS) for
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Fig. 1 Schematic of critical mechanisms affecting cardiomyocyte contraction targeted by drugs. Most therapeutics that target the heart or have off-target
effects on the heart fall within the mechanisms shown. 1: Since no beta-adrenergic agonists are present in in vitro cultures with deﬁned medium, this
category is not relevant in this study. 2: This group is small and the mechanisms are not speciﬁc. For example, while blebbistatin reduces contractility, it
also affects cardiomyocyte electrophysiology. Therefore, this category is not included in this study. Asterisk: These compounds exhibit both PDE inhibiting
and myoﬁlament Ca2+ sensitizing properties, with the dominant mechanism typically depending on the concentration
Table 1 Hypotheses table
Co= Co+Ca Co+Myosin Co+cAMP Co-Ca Co−Tox
Typical compound Aspirin Ouabain Omecamtiv Mecarbil β-adrenergic agonist Verapamil Doxorubicin (long term)
References 42–44 15,45,46 17,47,48 6,49,50 51–53 21,54,55
Kinetic parameters
Action potential (AP)
Amplitude = = = = ↓ ↓
trise = ↓ = ↓ NOT ↓ ↑
tAPD = NOT= = ↓ ↓ NOT ↑
Triangulation = ↓ = ↓ ↓ ↑
Calcium transient (Ca)
Amplitude = ↑ = ↑ ↓ ↓
tto peak = NOT ↓ NOT ↑ ↓ ↓ NOT ↑
tdecay = NOT ↓ NOT ↑ ↓ ↓ NOT ↑
Contraction (Co)
Amplitude = ↑ ↑ ↑ ↓ ↓
tcontraction = NOT ↓ ↑ ↓ ↓ NOT ↑
trelaxation = NOT ↓ NOT ↓ ↓ ↓ NOT ↑
Expected effects on kinetic measures of action potential (AP), cytosolic calcium transient (Ca) and contraction (Co) per contractile mechanism of action (MOA). ↓: decrease; ↑: increase; =: no difference.
NOT [effect] means all other effects than [effect] might be expected, depending on the speciﬁc drug within the MOA category
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each possibility (↑, ↓ or= ) using the following formulae:
PDF xð Þ ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2πsd2mean
p  e
xmeanvehicleð Þ2
2sd2mean ð1Þ
PS¼ xð Þ ¼ 10PDF xð ÞPDF meanvehicleð Þ ð2Þ
PS" xð Þ ¼
0; x < meanvehicle
10 PS¼ðxÞ; x  meanvehicle

ð3Þ
PS# xð Þ ¼
10 PS¼ðxÞ; x  meanvehicle
0; x > meanvehicle

ð4Þ
where sdvehicle is the standard deviation of the vehicle measure-
ments. Since we are interested in ﬁnding the most likely
hypothesis rather than looking at absolute values resulting from
these formulae and PS¼ xð Þ  PS" xð Þ and PS¼ xð Þ  PS" xð Þ if ≈
meanvehicle, it is reasonable to assume PS↑(x)= 0 and PS↓(x)= 0 if
x < meanvehicle and x > meanvehicle, respectively.
The process is repeated for the 10 kinetic parameters according
to Table 1 and all PS values are added to reach a total PS between
0 and 100. The hypothesis with the highest total score is most
likely to indicate the relevant MOA.
Development of the Triple Transient Measurement system.
Although a wide range of tools is available to measure the tran-
sients separately or as combinations of two, we aimed to measure
the three transients AP, Ca and Co simultaneously to decrease the
measurement-to-measurement variation and enable multiplexing
of all 10 parameters from a single biological sample at exactly the
same time. Since most dedicated measurement systems have
limited ﬂexibility in the setup itself (e.g. measuring only
impedance-based contractility or extracellular electrical ﬁeld
properties by multi electrode arrays; MEAs) or in the throughput
or invasiveness (e.g. patch clamp electrophysiology requiring
individual cell impalement) an optical system was designed that
had a sampling speed >300 frames per second (fps) as required to
capture all hiPSC-CM transient kinetics accurately. AP, Ca and Co
can be measured optically using ﬂuorescent voltage- and calcium
sensitive dyes and ﬂuorescent membrane labelling combined with
the analysis algorithm MUSCLEMOTION12, respectively.
Simultaneous ﬂuorescent imaging can be done using
wavelength separation in the emission pathway or by high-
speed switching between wavelengths. Since wavelength separa-
tion decreases the light intensity and exposure times had to be
low due to the sampling speed, high-speed switching was the
method of choice in combination with a multiband ﬁlter to
avoid slow mechanical switching. In turn, this limited the
choice of dyes since they had to have no or minimal
overlapping excitation wavelengths. ANNINE-6plus, Rhod 3
and CellMask Deep Red were selected together with the
appropriate excitation LEDs emitting at 470 nm, 560 nm and
656 nm (Supplementary Fig. 1). To investigate the extent to
which the optical sensors affected baseline electrophysiological
responses, hiPSC-CMs previously derived from patients with
Jervell and Lange-Nielsen Syndrome (JLNS)26 were plated on
MEAs and the spontaneous electrophysiological response was
measured before and after incubation with the dyes (Supple-
mentary Fig. 2). Inferential statistics with ANOVA was
performed and no signiﬁcant effect of the sensors was found.
In addition, values found were similar to those previously
reported27. Finally, the LEDs and camera where synchronized
using a computer with data acquisition card and custom
software to reach a sampling speed of 1000 fps, resulting in a
sample speed of 333 fps per transient, which allowed us to reach
an effective synchronisation among transients. Due to the high
sampling speed required, the camera exposure time was limited
which, in turn, limited the levels of ﬂuorescent signal that could
be detected in the camera; we therefore ampliﬁed the light using
an image intensiﬁer.
Our algorithm uses vehicle measurements to deﬁne the
baseline population, so a ﬁxed pacing frequency of 1.2 Hz was
chosen for all measurements instead of an adaptive frequency.
The latter would have required frequency correction for all
parameters but the mathematical models for such correction are
imperfect for action potentials and unavailable for calcium and
contraction. hiPSC-CMs were stimulated using a method
developed in-house to produce a block pulse that was chosen to
be as short as possible (2–10 ms) and used a voltage as low as
possible (10–18 V) while still activating the cells. The settings
were kept consistent while measuring under baseline conditions
and after drug addition. All wells were measured, and thus
stimulated, only twice and no changes were seen in susceptibility
of response to the ﬁeld stimulation during the second measure-
ment. A 50% medium change during drug addition minimized
electrolysis effects. To test whether there was any crosstalk
between the ﬂuorescent signals of the different dyes, different
wells of Pluricyte hiPSC-CMs where exclusively labelled with each
of the three dyes and exposed to all three LED wavelengths
individually (Supplementary Fig. 3). Assessment of the ﬂuores-
cence intensity revealed that ANNINE-6plus and Rhod 3 signals
were only present in response to 470 and 560 nm wavelengths,
respectively. CellMask Deep Red showed a modulating image
intensity due to contraction usable for MUSCELMOTION
analysis only at 656 nm. An overview of the setup is shown in
Fig. 3a.
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Fig. 2 Experimental setup and example output. a Schematic layout of the experimental setup; b output example of contraction amplitude in a
concentration-response plot in which individual points show averaged values of a well and the red dotted line indicates the known therapeutic
concentration; c corresponding probability density function (grey) and PS↑ and PS↓ (red lines) describing the three spaces for the three Probability Scores
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Data extraction and processing. For each measurement point,
7 s of recording were made at 1000 fps using a spatial resolution
of 720 × 720 pixels yielding a ﬁle size of 3.6 GB. This large
amount of data is then handled using automated data processing
algorithms. First, the total ﬁle is split into three separate stacks
corresponding with the three transients AP, Ca and Co. Next, the
image intensity plots are extracted from all three image stacks
(Fig. 3b). This yields the raw AP signal, Ca signal and the motion
artefact (MA) signal. Since CellMask Deep Red (i.e. the ﬂuor-
ophore that is the origin of the MA signal) is colocalized with the
VSD in the membrane of the hPSC-CMs and recorded simulta-
neously with the VSD signal, we could use the MA signal for
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Fig. 3 Triple Transient Measurement system for determining AP, Ca and Co simultaneously. a Hardware setup: the hiPSC-CM model of interest (2D or 3D)
is incubated with the voltage sensitive dye (ANNINE-6plus), calcium sensitive dye (Rhod 3) and cell membrane label (CellMask Deep Red) used for
measuring contraction. The hiPSC-CMs are excited using three rapidly alternating LEDs which are synchronized with a high-speed camera. The camera
receives the emitted signal from the hiPSC-CMs after photon ampliﬁcation by the image intensiﬁer. The data are then fed into the data processing pipeline.
b The video frames are split into three stacks that contain the information regarding the AP (blue), Ca (yellow) and Co (red). The information of each stack
is extracted by either plotting the intensity changes and/or applying MUSCLEMOTION. c The data are then “cleaned” to remove the motion artefacts,
invert the signal when necessary, calculate ΔF/F, apply a minimal ﬁlter and/or average the events within one recording. d The data are quantiﬁed by
summarizing the kinetic parameters of interest determined in Table 1. e Finally, the data are plotted and meanwhile fed into the hypothesis algorithm
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ratiometric correction of the AP and Ca signal28. Meanwhile, the
Co stack was also analysed using MUSCLEMOTION to quantify
hiPSC-CM contraction.
Next, the data were cleaned by applying MA correction, the AP
signal inverted (since the signal intensity of ANNINE-6plus
decreases with depolarization), the pseudo ratio ΔFFmin for AP and
Ca calculated, a minimally moving average ﬁlter (2 frames)
applied and ﬁnally ﬁve events in the recording averaged29 after
checking whether the interpeak distance corresponded to the
pacing frequency (Fig. 3c). The data were then summarized by
the kinetic parameters described in Table 1 (Fig. 3d). After these
steps were repeated for all the measurements, concentration-
response plots were generated per kinetic parameter for visual
interpretation of the results (Fig. 3e). Finally, the data were fed
into the hypothesis algorithm.
hiPSC-CM drug response. To validate the setup and algorithm, a
set of 12 drug responses was selected that comprised at least all
MOA identiﬁed in Table 1 once. Brieﬂy, commercial hiPSC-CM
monolayers were cultured in glass-bottomed 96-well plates. Per
drug, ﬁve concentrations and a vehicle (DMSO) were tested.
These conditions were each tested in ﬁve different wells and three
individual areas were measured per well (Fig. 2a). The area was
measured before and after drug- or vehicle incubation (30 min at
37 °C). Representative transients normalized to baseline of vehicle
measurements and an illustrative concentration per drug are
shown in Fig. 4. The vast amount of data (±600 GB per drug) was
then automatically evaluated and quantiﬁed.
Next, the analysis algorithm was applied to the data. For each
drug at and each concentration, the hypothesis table was populated
using the calculations of the probability scores and summarized
(Supplementary Table 1). As described earlier, the highest
summarized value identiﬁed the MOA. The resulting assignments
per concentration are shown in Supplementary Table 2 (column
‘ALL’). The algorithm accurately indicated the correct MOAs for 10
of the 12 drugs when analysing the response of AP, Ca and Co. A
comparison with conventional statistical methods per parameter
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Fig. 4 Averaged representative transients of hiPSC-CMs in response to vehicle (DMSO) and drugs. All measurements were normalized to their individual
baseline measurements. Cells were paced at 1.2 Hz. Simultaneous measurements show action potential (blue), cytosolic calcium (orange) and contraction
(red) of Pluricytes under baseline conditions and in response to 0.3 µM epinephrine (a), 100 µM pimobendan (b), 0.1 µM verapamil (c), 30 µM captopril
(d), 3 µM forskolin (e), 30 µM aspirin (f), 3 µM doxorubicin (g), 0.3 µM omecamtiv mecarbil (h), 0.3 µM levosimendan (i), 3 µM atenolol (j), 10 µM
sunitinib (k) and 1 µM ouabain (l)
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per drug per dose can be found in Supplementary Table 3. It is
evident that the algorithm is typically not triggered by small
changes that might not be physiologically relevant (e.g. captopril at
1 µM) while it does indicate a relevant change in certain cases
although no statistical differences are evident in the individual
parameters (e.g. omecamtiv mecarbil at 0.03 and 0.3 µM). In some
cases, small ‘signiﬁcant’ changes in single parameters might not be
physiologically meaningful while a combined system of changes
does more robustly indicate a relevant cell response.
Both PDE3-inhibiting drugs levosimendan and pimobendan
had no effect assigned by the algorithm, whilst the opposite would
be expected based on the literature, where the calcium sensitizing-
and PDE3-inhibiting effects of the drugs should cause a positive
inotropic effect30,31. Reviewing the data manually also did not
show any changes compared to vehicle. This lack of effect is most
likely due to by hiPSC-CM immaturity32,33 or incubation time.
Furthermore, one unexpected observation was made with
atenolol, which binds to the β1-adrenoceptor and competes with
endogenous neurostimulators. Because neurostimulators are not
present in serum-free hiPSC-CM cultures, no effect was expected,
but a myosin-related increase in Co was seen at 0.3 μM. However,
calcium current enhancement and inhibition have been reported
previously in agonist-free conditions34 which might explain the
increase in APt,rise at 0.3 μM. Therefore, while the assignment of a
myosin related contractile increase is incorrect, the assignment of
‘no effect’ is also questionable. Since the dataset generated is too
large to include in standard ﬁgures, an interactive online tool was
developed to give readers access to all data and both qualitative
and quantitative insight in the data and analysis. In addition, the
tool allows comparison to traditional statistics. Baseline statistics
and raw concentration-response curves are also available to
demonstrate the high inter-measurement variation and time-
dependent effects, respectively, which is the reason for normal-
ization to the vehicle. The tool is available at https://bjvanmeer.
shinyapps.io/TTM-algorithm/.
Comparison to AP, Ca or Co only. In addition, the assignments
that resulted from only analysing Vo, Ca or Co are listed in
Supplementary Table 2 (column ‘AP-’, ‘Ca-’ and ‘Co only’). As
expected, assignments of the individual parameters are not as
accurate as analysis of all parameters together and this gives
further strength to our combined analysis strategy. The individual
parameters are often incorrect in identifying the MOA and more
frequently show inconsistent responses throughout the different
concentrations. Another issue, which can also be seen in Table 1,
is that some parameters are unable to distinguish between certain
MOAs (i.e. AP only is unable to distinguish between Co= and
CoþMyosin; Co is unable to distinguish between Co
þ
Myosin and Co
þ
Ca).
Other platforms that use multi parameter assessments in
hPSC-CMs exist but differ from the TTM system. The system
developed by Klimas et al. relies on optogenetics and therefore
requires cell lines in which the optogenetic actuators have been
transfected or stably inserted, adding signiﬁcant complexity and
decreasing ﬂexibility35. Furthermore while the channelrhodop-
sin2 enables the cells to be paced, it has to be controlled by light
pulses which limits the time for ﬂuorescence recording and
therefore only allows simultaneous measurements of two
parameters (voltage and calcium) rather than all three. While
the CellOPTIQ system36 (Clyde Biosciences) can record all three
parameters, this can only be performed sequentially and not
simultaneously like the TTM system. Additionally, the CellOP-
TIQ system has a lower frame rate which might limit the accuracy
especially for the action potential. However, the resulting output
is similar to that obtained with the TTM system, meaning that
similar analysis using the hypothesis-based model for the
classiﬁcation of pharmacological effects might be possible.
Similarly, Christoph et al. recently published a more complex
method to perform accurate 3D voltage mapping37. While only
suitable for 3D tissues and more focused on the spatiotemporal
patterns during ﬁbrillation, the output data from this system
might be suitable for the hypothesis-based algorithm.
Automated evaluation of the output data generated by different
systems using the hypothesis-based algorithm would enable
comparable interpretation of the results. Since the algorithm is
based on the vehicle population of the system it would not be
limited by differences between absolute values or percentages of
change which often make head to head comparison of different
techniques difﬁcult or impossible. More generally, user bias is
greatly reduced using automated interpretation. However, currently
all systems still rely on non-automated manual response
interpretation.
In summary, it is now widely recognized that predicting
clinical impact of drugs using in vitro and/or in silico models and
obtaining more insight in the mechanisms underlying individual
responses to drugs or disease mutations is crucial for developing
new therapeutic compounds, treatments and strategies. The work
here contributes to this by combining multiple functional
readouts in one system with automatic quantitative assessment
not subject to operator bias. We focussed speciﬁcally on
contractile mechanisms in cardiac models while others have
integrated qualiﬁcation of other drug types such as chemother-
apeutics38. Combining such scores might ultimately lead to an
integrated cardiac safety score. The majority of hiPSC-CMs
remain immature in most standard laboratory formats and are
therefore associated with a high inter-sample variability. Whilst
methods are emerging that can promote maturation7,8,39,40,
advanced multiplexed tools as described here can help identify
immature features and suggest possible methods to address this
and reduce inter-sample variability. The method was demon-
strated here on monolayer cultures of hiPSC-CMs, but is equally
applicable to more complex multicellular and 3D formats.
Ultimately, multiplexing not only functional readouts but also
those from genetics, metabolomics and proteomics could provide
truly predictive models for insight into the cellular mechanisms
underlying drug response and pathology in the human heart.
Methods
TTM system. An Eclipse Ti microscope (Nikon) was ﬁtted with a 3 high-power
LED system (Mightex; 470 nm, 560 nm and 656 nm) including collimators and
excitation ﬁlters (Semrock; 470 ± 14 nm, 544 ± 12 nm, 650 ± 7.5 nm). The LEDs
were controlled using a custom-made current source that was coupled to a 32
channel PCI DAQ Card (National Instruments). Furthermore, an image intensiﬁer
(Photonis, the Netherlands) was coupled to a high-speed camera (Optronis
GmbH), which was triggered by the DAQ card using a custom Labview (National
Instruments) program. The microscope was ﬁtted with a custom-built environ-
mental chamber that allowed measurements to be performed at 37 °C and 5% CO2.
All analyses were performed using ImageJ (NIH) and R (R Foundation for Sta-
tistical Computing).
hiPSC-CM cell culture. Black glass-bottom 96-well plates (Greiner) were coated with
1:100 Matrigel (Sigma–Aldrich) in DMEM F12 (Sigma–Aldrich). Per drug, one vial of
commercial hiPSC-CMs (Pluricytes; Ncardia, catalogue number PCK-1.5, kindly
provided by Ncardia) was thawed according to manufacturer’s instructions in Plur-
icyte medium (PCM; Ncardia, catalogue number PCK-1.5, kindly provided by
Ncardia). To allow dye incubation and measurements in parallel, cells were dis-
tributed over two plates in 15–20 wells (40k cells per well in 100 μL). RevitaCell
(1:100, ThermoFisher Scientiﬁc) was added to the culture medium to improve cell
recovery. Empty wells around the wells with hiPSC-CMs were ﬁlled with 200uL of
PBS−/− (Gibco) to minimize evaporation. Cells were refreshed with 200 μL PCM
medium at day 1 and day 4 or 5 after plating. All measurements for each drug were
always performed either on day 5 and 6 or day 6 and 7 after plating.
Dye and drug incubation. ANNINE 6-plus (Sensitive Farbstoffe GbR), Rhod-3
(Invitrogen) and CellMask Deep Red (Invitrogen) with stock concentrations 0.5 g
per L, 10 mM and 5mg per mL were mixed in 500 μL PCM in ratios of 1:833, 1:833
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and 1:100, respectively. 50 μL of the mix was added to each well and incubated for
20 min at 37 °C. Before starting baseline measurements, wells were refreshed with
200 uL per well of PCM and left for 10 min at 37 °C to recover.
After baseline measurements 100 μL medium was removed and 100 μL of drug
solution in PCM (200% of the ﬁnal concentration) was added and the hiPSC-CMs
incubated for 30 min at 37 °C. All drugs were reconstituted in DMSO
(Sigma–Aldrich) with solutions prepared to ensure a ﬁnal concentration of 0.1%
DMSO in each well. Vehicle incubations were done similarly using PCM plus 0.1%
DMSO. All drugs, apart from ouabain (Sigma–Aldrich), were kindly provided by
GlaxoSmithKline (United Kingdom).
MEA Recordings of hiPSC-CMs. Extracellular ﬁeld potentials from hiPSC-CMs
plated on MEAs were recorded (recording duration 2 min) using a 96-well Mul-
tiwell MEA system (Multichannel Systems GmbH) at 37 °C running the Multiwell-
Screen software. Beating monolayers of hiPSC-CMs were incubated with ﬂuor-
escent reporters following the protocol developed for the TTM System, with DMSO
concentrations balanced accordingly. After incubating the hiPSC-CMs with the
dyes for 20 min, the beating monolayers were washed with warm BPEL and the
electrophysiological properties of the monolayers assessed at two different time
points after the washout (2–4 min and 13–15 min). Data were exported with
Multiwell-Analyzer and visualised through a custom-made R script. The inter-
pretation of QT and RR intervals was done using Clampﬁt (analysis module from
Axon™ pCLAMP™ 11)41.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
We have developed an interactive webtool to access the vast amount of data more easily
and intuitively. The tool is available at https://bjvanmeer.shinyapps.io/TTM-algorithm/.
The source data underlying Supplementary Table 2, Supplementary Table 3 and
Supplementary Fig. 2 are provided as a Source Data ﬁle. In addition, the source data of all
measurements is provided as Source Data ﬁle. In addition, the data can be found at the
Dryad Digital Repository under the following https://doi.org/10.5061/dryad.67c92vm.
Code availability
Source codes for the software are available on https://gitlab.com/bjvanmeer/ttm-
algorithm/.
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